MedTrace Logo

Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases

NCT00466102 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2012-08-30

No results posted yet for this study

Summary

The purpose of this study is to determine wether RAD001 can inhibit growth of tumour cells and/or stop the formation and activity of bone degrading osteoclasts.

Conditions

Interventions

DRUG

RAD001

Tablet of 5 mg, 2 tablets (10 mg) are taken once daily during study therapy

DRUG

Placebo

2 tablets are taken once daily during study therapy

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • GBG Forschungs GmbH

    lead OTHER

Principal Investigators

  • Nicolai Maass, MD, Prof. · Universitätsfrauenklinik Aachen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2010-12-31
Completion
2012-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00466102 on ClinicalTrials.gov